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Hyperprolactinemia is a common cause of menstrual disturbances affecting
young women. There is a diversity of causes, from physiological, such as preg-
nancy, to pharmacological and pathological, such as hypothyroidism. Renal and
hepatic failure, intercostal nerve stimulation by trauma or surgery, prolactino-
mas, other tumors in the hypothalamus-pituitary region, as well as macropro-
lactinemia can also be considered. Identifying the correct cause is important to
establish the correct treatment. Should all these causes be ruled out and pituitary
imaging revealed as negative, idiopathic hyperprolactinemia is therefore
diagnosed.
In symptomatic patients, treatment with dopaminergic agonists is indicated. As
for the asymptomatic hyperprolactinemic individuals, macroprolactinemia
should be screened, andonce it is detected, there is no need for pituitary imaging
study or for dopaminergic agonist use. (J Clin Endocrinol Metab 97: 2211–2216,
2012)
Case Report
A 33-yr-old woman had her serum prolactin (PRL) as-sayed during a routine gynecological evaluation,
and the resultwas147ng/ml (normal range, 2.5- 15ng/ml;
immunofluorometric assay, Wallac AutoDelfia, PerkinElmer
Life Sciences, Boston, MA). After menarche at 15 yr, she
presented regular menses and no galactorrhea or libido
disturbances.
She was on oral contraceptive pills until she was 28
yr old,when she stopped contraception to try pregnancy
for 2 yr without success. She denied using any potential
drug that could induce hyperprolactinemia. Transvag-
inal ultrasound and sellar magnetic resonance imaging
(MRI) (Fig. 1) were performed, with no abnormalities
detected. To restore her fertility, treatment for hyper-
prolactinemia was suggested, and she was then referred
to our institution.
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in U.S.A.
Copyright © 2012 by The Endocrine Society
doi: 10.1210/jc.2011-2976 Received October 28, 2011. Accepted April 17, 2012.
Abbreviations: APA, Antipituitary antibody; DA, dopamine agonist; MRI, magnetic reso-
nance imaging; PCOS, polycystic ovary syndrome; PEG, polyethylene glycol; PRL, prolactin.
Accreditation and Credit Designation Statements
The Endocrine Society is accredited by the Accreditation
Council for Continuing Medical Education to provide con-
tinuing medical education for physicians. The Endocrine
Society has achieved Accreditation with Commendation.
The Endocrine Society designates this Journal-based CME ac-
tivity for a maximum of 1 AMA PRA Category 1 Credit™.
Physicians should claimonly the credit commensuratewith the
extent of their participation in the activity.
Learning Objectives
Upon completion of this educational activity, participants
should be able to:
• Identify the etiology of hyperprolactinemia amongst
physiological, pharmacological and pathological as hypo-
thyroidism, renal and hepatic failure, intercostal nerves
stimulation, prolactinomas and other tumors of the sellar
region.
• Make the clinical diagnosis in order to direct proper lab-
oratorial and imaging diagnosis when indicated.
Target Audience
This Journal-based CME activity should be of substantial
interest to endocrinologists.
Disclosure Policy
Authors, editors, and Endocrine Society staff involved in plan-
ning this CME activity are required to disclose to The Endo-
crine Society and to learners any relevant financial relation-
ship(s) of the individual or spouse/partner that have occurred
within the last 12 months with any commercial interest(s)
whose products or services are discussed in the CME content.
The Endocrine Society has reviewed all disclosures and re-
solved or managed all identified conflicts of interest, as appli-
cable. Disclosures for JCEM Editors are found at http://www.
endo-society.org/journals/Other/faculty_jcem.cfm.
Marcello D. Bronstein, M.D., Ph.D., Andrea Glezer, M.D.,
Ph.D., and Editor-in-Chief, Leonard Wartofsky, M.D., re-
ported no relevant financial relationships.
Endocrine Society staff associated with the development of
content for this activity reported no relevant financial
relationships.
Acknowledgement of Commercial Support
This activity is not supported by grants, other funds, or in-
kind contributions from commercial supporters.
Privacy and Confidentiality Statement
The Endocrine Society will record learner’s personal infor-
mation as provided on CME evaluations to allow for issu-
ance and tracking of CME certificates. No individual per-
formance data or any other personal information collected
from evaluations will be shared with third parties.
Method of Participation
This Journal-based CME activity is available in print and
online as full text HTML and as a PDF that can be viewed
and/or printed using Adobe Acrobat Reader. To receive a
maximum of 1AMAPRACategory 1 Credit™participants
should review the learning objectives and disclosure infor-
mation; read the article and reflect on its content; then go to
http://jcem.endojournals.org and find the article, click on
CME for Readers, and follow the instructions to access and
complete the post-activity test questions and evaluation
achieving a minimum score of 70%. If learners do not
achieve a passing score of 70%, they have the option to
change their answers andmake additional attempts to achieve
a passing score. Learners also have the option to clear all an-
swers and start over.
To complete this activity, participants must:
• Have access to a computer with an internet connection.
• Use a major web browser, such as Internet Explorer 7,
Firefox 2, Safari, Opera, or Google Chrome; in addi-
tion, cookies and Javascriptmust be enabled in thebrows-
er’s options.
The estimated time to complete this activity, including review
of material, is 1 hour. If you have questions about this CME
activity, please direct them to education@endo-society.org.
Activity release date: July 2012
Activity expiration date: July 2014
S P E C I A L F E A T U R E
A p p r o a c h t o t h e P a t i e n t
J Clin Endocrinol Metab, July 2012, 97(7):2211–2216 jcem.endojournals.org 2211
Background
Hyperprolactinemia, defined by a high level of serumPRL
above the standard upper limit of normal range, is the
most common hypothalamus-pituitary dysfunction. In
nonpregnant and non-nursing women, the clinical picture
mimics the puerperal period, characterized by irregular
menses or amenorrhea, galactorrhea, infertility, and a de-
crease of libido. In men, hypogonadism, infertility, and
libido impairment could be found. Additionally, patients
with hyperprolactinemia can also exhibit hypopituitar-
ism, visual impairment, and headache (1) due to an ex-
panding mass.
Therefore, nonphysiological hyperprolactinemia must
be recognized and treated. Indications for measuring se-
rum PRL include galactorrhea, irregu-
lar menses, infertility, and pituitary
tumors.
Causes of hyperprolactinemia are
listed on Table 1. Nevertheless, the aim
of this article is to point out and discuss
only the differential diagnosis of hyper-
prolactinemia associated with negative
imaging of the hypothalamus-pituitary
region.
Many causes of hyperprolactinemia
can be suspected during anamnesis, such
as drug use, renal or hepatic failure, and
hypothyroidism. In patients with suspi-
cious drug-induced hyperprolactinemia,
it is recommended to perform new PRL
evaluationafterdiscontinuingmedicationforat least3to4d.
When drug withdrawal is unsafe, a MRI should be
taken to rule out a sellar mass. If drug-induced hyperpro-
lactinemia is confirmed, try to switch to an alternative
medication.
The dopamine antagonists like risperidone, haloperidol,
andsulpirideare themainclassofpsychoactivedrugs leading
tohyperprolactinemia,andtheyshouldbediscontinuedonly
bypsychiatrists. If it is notpossible to switchorwithdrawthe
drug, hormonal replacement for hypogonadism is indicated,
because dopamine agonists (DA) may oppose the beneficial
antagonismof antipsychotic drugs (2).Aripiprazole, ziprasi-
done, and olanzapine are atypical antipsychotic drugs that
donotcausehyperprolactinemia.Drugmechanisms that can
cause hyperprolactinemia are: antagonistic effect on D2 re-
ceptors (antipsychotic drugs and gastrointestinal drugs as
metoclopramide and domperidone), hypothalamic dopa-
mine blockage (verapamil), and inhibition of enzyme that
converts L-dopa to dopamine by -methyldopa (2).
Decreased PRL clearance and reduced inhibitory do-
paminergic tonus by uremia are responsible for hyperp-
rolactinemia, which is found in up to 30% of the cases in
patients suffering from renal failure. Serum PRL levels
depend on renal failure degree, and they can only return to
normal status after a successful kidney transplant (3, 4).
Marked hyperprolactinemia can be found in patients with
renal failure using drugs that could induce hyperprolactine-
mia (5). Yavuz et al. (6) did not find macroprolactinemia in
patients affected with renal failure. Hyperprolactinemia is
defined by a high level of serum PRL, above the standard
upper limit, and obtained without excessive venipuncture
stress. Macroprolactinemia is defined when there is a prev-
alence of macroprolactin as the major circulating PRL iso-
form, which will be detailed below in this section.
About 60% of cirrhotic patients accuse the presence of
mild hyperprolactinemia (7),without correlation between
FIG. 1. Sellar MRI depicting normal pituitary gland I; coronal views without (A) and with (B)
gadolinium enhancement.
TABLE 1. Causes of hyperprolactinemia
Physiological: pregnancy and lactation, physical activity,
mammary stimulation
Pharmacological: antipsychotics, especially neuroleptics,
antidepressants, opiates, and cocaine; antihypertensive
medications (verapamil, methyldopa, reserpine);
gastrointestinal medications (metoclopramide,
domperidone); protease inhibitors; and estrogens
Associated to general diseases: renal failure, liver failure
Associated to endocrine diseases
Hypothyroidism
PCOS
Pituitary adenomas
Prolactinomas
Mixed secretion of PRL/GH
Cushing’s disease, Nelson’s syndrome, Addison’s disease
Pituitary stalk disconnection
Nonpituitary tumors: craniopharyngioma, meningioma,
germinoma, metastasis
Pituitary tumors other than prolactinomas
Infiltrative lesions: sarcoidosis, histiocytosis, lymphomas,
hypophysitis
Postoperative, radiotherapy
Intrasellar arachnoidocele (empty sella)
Breast or thoracic surgery, chest wall trauma (intercostal nerves
stimulation)
Macroprolactinemia
Idiopathic
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PRL levels and the severity of liver failure. Etiopathogen-
esis is unknown (8).
Themajormechanismcausinghyperprolactinemia inpri-
mary hypothyroidism is an increase in the levels of TRH,
which stimulates PRL secretion (9).
Moreover, other mechanisms such as reduced PRL
clearance, decreased sensitivity to the suppressant effect of
dopamine on PRL synthesis, and decreased circulating
thyroid hormone levels could be involved. Hyperpro-
lactinemiawas found inup to40%ofpatientswith clinical
hypothyroidism. Interesting enough, Hekimsoy et al. (10)
found hyperprolactinemia in 22% of patients with sub-
clinical hypothyroidism (defined by increased TSH with
normal serum thyroid hormones). Serum PRL levels re-
turn to normal after the replacement of L-thyroxine. Con-
cerning the clinical picture, Raber et al. (11) did not find
differences in the prevalence of irregular menses or galac-
torrhea in 1003 hypothyroid patients with or without
hyperprolactinemia.
Previous studies observed hyperprolactinemia in up to
30%ofpatients suffering frompolycystic ovary syndrome
(PCOS), and the influence of estrogen levels and dopami-
nergic tonus reduction were referred to as possible causes
(12). More recently, a physiopathological link between
PRL and PCOS was not confirmed, and their relationship
was considered a fortuitous association (13, 14).
Nipple stimulation in nonpregnant women also in-
creases the level of PRL due to a neurogenic reflex, an
afferent pathway independent from dopaminergic neu-
rons. Chest wall injury such asmechanical trauma, burns,
surgery, and herpes zoster of thoracic dermatomes can
also cause hyperprolactinemia (15). Reported cases of ga-
lactorrhea associated with hyperprolactinemia were also
described after breast augmentation surgery and nipple
piercing (16, 17). Breast stimulation, such as clinical ex-
amination (18), ultrasound, ormammography, has only a
minimal effect on serumPRL levels innormalwomen (19).
Macroprolactinemia is defined by the presence ofmore
than 50% of serum PRL as macroprolactin (or big-big-
prolactin), an isoform of high molecular weight and low
biological activity (20). Macroprolactin causes hyperpro-
lactinemia as a consequence of low renal PRL clearance
and a decreased stimulation of dopaminergic tonus.
Macroprolactinemia is responsible for hyperprolactine-
mia in 10 to 46%of the cases (21), and it should be screened
in the following situations: individuals with high PRL levels
but no indications of clinical symptoms, atypical clinical pic-
ture, conflicting PRL results in distinct assays, and delayed
decline of serumPRL levels with the usual doses of DA (22).
If monomeric prolactin level is also high, clinical picture can
be present, despite the presence ofmacroprolactinemia (23).
Screening by precipitationwith polyethylene glycol (PEG)
is widely performed due to its low cost and practicability.
The detection of macroprolactinemia via PEG precipita-
tion was validated against gel filtration chromatography,
the “gold standard” method to evaluate PRL isoforms.
Recovery rates lower than 30 to 50% of total serum PRL
levels in the supernatant are compatible with macropro-
lactinemia (23). Prolactin level measurement in macrop-
rolactinemia serumdepends on the PRL assay used. In one
study, nine different immunoassays were tested in 10 sera
containing macroprolactinemia, and serum PRL level dif-
ferences ranged from 2.3 to 7.8-fold (24).
Although macroprolactin is, in general, composed of
a complex formed with an IgG and a monomeric PRL
(25), macroprolactinemia does not seem to be linked to
autoimmune diseases (26). Macroprolactin levels re-
main stable for a long time. Vallette-Kasic et al. (27)
evaluated 106 macroprolactinemic individuals. Prolac-
tin levels ranged from 20 to 663 ng/ml, and levels below
100 ng/ml are responsible for more than 90% of cases.
Although PRL levels remained almost unchanged, large
individual variations occurred. Seven women became
pregnant during follow-up, and deliveries were unevent-
ful. These data confirmedmacroprolactinemia as a benign
condition in terms of fertility. Infertility originating from
other causesmaycoincidentallyoccur inmacroprolactine-
mic women (28).
If the aforementioned causes were ruled out, hyper-
prolactinemia should be defined as idiopathic. Factors
like the lack of sensitivity of imaging methods, such as
a plain sellar x-ray machine and computerized tomog-
raphy scan in the past, as well as the evidence of a hard-
to-detect (even for MRI standards) presence of microp-
rolactinoma are some possible explanations for a
symptomatic patient with idiopathic hyperprolactine-
mia (29). Alternatively, De Bellis et al. (30) found a high
prevalence of antipituitary antibodies (APA) in 25.7% of
patients with idiopathic hyperprolactinemia, whereas all
patients with microprolactinomas and normal controls
were negative for APA. Among 17 patients positive for
APA, six had other pituitary deficiencies. These findings
pointed to a pituitary autoimmune involvement causing
hyperprolactinemia, and it must be suspected in patients
with idiopathic hyperprolactinemia and personal or fa-
milial history of autoimmune disease. However, no other
studies reproduced these findings, and APA testing is not
commercially available.
Diagnostic and Therapeutic Strategies
Before proceeding with the imaging investigation, preg-
nancy, hypothyroidism, renal or hepatic failure, anddrugs
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must be ruled out as causes of hyperprolactinemia because
pituitary incidentaloma can be found in 10% of sellar
MRI in normal individuals, becoming, therefore, a diag-
nostic pitfall (31). In asymptomatic patients, macropro-
lactinemia should be excluded, and if positive, sellar MRI
is not indicated (32). As a matter of fact, prolactinomas
could be associated to macroprolactinemia, but in this
case patients are usually symptomatic, and they would
need an imaging study (33).
Dynamic testing for PRL (with TRH and dopamine
antagonist drugs) is not useful in differential diagnosis of
hyperprolactinemia, and it is not recommended by The
Endocrine Society’s guidelines (34).
Stress could increase PRL secretion; therefore, levels
that are just outside the normal range should be repeated
(35). Muneyyirci et al. (36) found that nearly 30% of
hyperprolactinemia was stress related in 70 women with
hyperprolactinemia, andVieira et al. (37) described a sim-
ilar percentage: 25.5% in 157 patients. If mild hyperpro-
lactinemia persists in an asymptomatic patient without
macroprolactinemia, PRL evaluation should be repeated
after 30 min of rest. Figure 2 shows an algorithm with
diagnostic strategies.
Treatment is indicated in symptomatic patients with
idiopathic hyperprolactinemia. DA are the therapy of
choice because they promote serum PRL normalization,
restore hypothalamus-pituitary-gonadal axis function,
and abrogate galactorrhea. AmongDA, cabergoline is the
first choice due to its efficacy and tolerability (38), al-
though data about its safety during pregnancy is far less
published compared with bromocriptine (34). Although
this drug was related to cardiac valve disease in patients
with Parkinson’s disease (39, 40), its effect in hyperpro-
lactinemic patients is still controversial (41). The necessity
of continuous treatment with DA should be reevaluated
because serum PRL levels may remain normal after drug
withdrawal. In a meta-analysis performed by Dekkers et
al. (42), 32% of patients with idiopathic hyperprolactine-
mia kept normal PRL levels after DA discontinuation.
This finding may reflect the natural history of idiopathic
hyperprolactinemia; as one study has shown, serum PRL
levels returned to normal without any treatment in one
third of patients (43). Therefore, in patients who attained
normoprolactinemia, treatment with DA should be peri-
odically discontinued according to The Endocrine Soci-
ety’s clinical guidelines for diagnosis and treatment of hy-
perprolactinemia (34).
Controversies and Areas of Uncertainty
The maintenance of DA during menopause is debatable
concerning two issues: pituitary tumor development
and cancer risk. Following up on patients with idio-
pathic hyperprolactinemia without treatment, analysis
showed thatmicroprolactinomas appeared in only 10%
of cases and no macroadenoma was reported in such
patients (43). Therefore, the need of continuous treat-
ment to prevent the growth of prolactinomas seems to
be unnecessary. Concerning the follow-up imaging, the
only potential conditions in which we suggest perform-
ing a new sellar MRI are the increase in PRL levels
during DA treatment or marked PRL elevation above
pretreatment levels after DA discontinuation.
As far as cancer risk is concerned, and although ex-
perimental evidence indicates that PRLmight play a role
in tumorigenesis of several cancers (44), the influence of
hyperprolactinemia in human beings is controversial. In
a prospective nested case-control study within the
Nurse’s Health Study cohort, serum PRL levels were
associated with a modestly increased risk of breast can-
cer, especially in breast cancer expressing estrogen/pro-
gesterone receptors (45). More recently, a cohort of
hyperprolactinemic hospitalized patients and outpa-
tients with prolactinomas was performed, and an over-
all increased risk of developing cancer was found, no-
tably in hematopoietic cancer in females and upper
gastrointestinal cancer in both genders, without evi-
dence of an increased risk of breast cancer in women
(46). To date, there is no indication of treating hyper-
prolactinemia intended to prevent cancer development.
Concerning macroprolactinemia, screening is con-
troversial. Some authors indicate screening for macrop-
rolactinemia in all hyperprolactinemic individuals to
FIG. 2. Algorithm for diagnostic strategies in hyperprolactinemia with
negative image.
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avoid unnecessary pituitary imaging and treatment
(23), whereas others suggest this procedure only if dis-
crepant findings were observed regarding clinical pre-
sentation or biological follow-up (27). In our opinion,
the macroprolactinemia “epidemics” could be avoided
by performing PRL assessment only in the presence of
hyperprolactinemia-related symptoms.
Doesmacroprolactin have any harm?Anaforoglu et al.
(47) studied platelet activation looking at P-selectin ex-
pression in hyperprolactinemic, macroprolactinemic, and
normoprolactinemic subjects, matched regarding blood
pressure, plasma lipids, waist circumference, and insulin
sensitivity status. Platelet activation was greater in hyper-
prolactinemic and macroprolactinemic patients. Reuwer
et al. (48) recently demonstrated the presence of PRL re-
ceptor in macrophages from atherosclerotic plaque, and
they hypothesized about a probable PRL role in the local
inflammatory response in the atherosclerotic plaque.Nev-
ertheless, the linkage of macroprolactinemia and athero-
sclerotic disorders is still controversial.
Returning to the Patient
Because our patient had regular menses and no galactor-
rhea, progesterone assay was performed during the luteal
phase, and PRL was then reassessed. Serum PRL level
reached 112 ng/ml and progesterone, 4.3 ng/ml (normal
range, 3.6–21.7 ng/ml), which is consistent with an ovu-
latory cycle. Due to the dissociation between laboratory
finding and clinical picture, screening ofmacroprolactine-
mia was performed by precipitation with PEG and pro-
duced a positive result: only 8% of total serum PRL was
recovered in the supernatant (7.2 ng/ml). We also per-
formed thyroid, renal, and hepatic assessments, which
were normal.
Hyperprolactinemia due to macroprolactinemia was
diagnosed, and no specific treatment for hyperprolactine-
mia was indicated. The cause of the patient’s infertility
should be further investigated.
Conclusions
In patients with persistent hyperprolactinemia, preg-
nancy, hypothyroidism, renal or hepatic failure, drugs and
macroprolactinemia should be ruled out before perform-
ing a sellarMRI. If no previous causes were identified and
the patient is symptomatic, pituitary imaging should be
done. If normal, idiopathic hyperprolactinemia is diag-
nosed, and DA treatment is indicated.
Macroprolactinemia is present in up to 46% of hyper-
prolactinemic individuals and should be screened in
asymptomatic individuals with high PRL levels. In the ab-
sence of symptoms, neither pituitary study imaging nor
medical treatment is indicated. Macroprolactinemic pa-
tients could present hyperprolactinemia-related symp-
tomswhen serummonomeric PRL level is outside the nor-
mal range, as in cases associated with prolactinoma, for
instance. In this situation, treatment with DA is recom-
mended.On the other hand, amacroprolactinemic patient
with normal monomeric PRL levels should be correctly
evaluated for irregular menses or infertility because other
causes for these symptoms could coexist with macropro-
lactinemia, and the use of DA is not recommended.
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